Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Trazimera [legacy through FY23] by Quarter
Trazimera (trastuzumab biosimilar) [legacy through FY23] — U.S. reported YoY (%) (%)
Pfizer Trazimera [legacy through FY23]: -48.0% in Q2 2023, down 54.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the Q2 2023 figure comes from
“|| Trazimera | 33 | 46 | (27%) | (26%) | 12 | 23 | (48%) | 21 | 23 | (6%) | (4%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Trazimera (trastuzumab biosimilar) [legacy through FY23] — U.S. reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2023 | Jul 2, 2023 | -48.0% | -54.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗ |
| Q1 2023 | Apr 2, 2023 | -69.0% | -152.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | -46.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
| Q3 2022 | Oct 2, 2022 | 47.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-10022022xex99.htm, filed 2022-11-01) ↗ |
| Q2 2022 | Jul 3, 2022 | 6.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-07032022xex99.htm, filed 2022-07-28) ↗ |
| Q1 2022 | Apr 3, 2022 | 83.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-04032022xex99.htm, filed 2022-05-03) ↗ |
Cite this data
StockData. (2026). Pfizer Trazimera [legacy through FY23] (%), quarterly Q1 2022–Q2 2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/trazimera-leg-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.